Company / Shareholders' Equity
Bioventus Inc. Shareholders' Equity History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$184.1M
FY2025
5-year range
$147.9M / $458.9M
FY2021-FY2025
Trend
+24.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity returned to growth in FY2025 after 3 years of decline, reaching $184M.
Based on SEC 10-K filings.
$184M in FY2025 with a 3-year CAGR of -17.3%.
Improved from $174M to $184M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -17.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -17.3%, indicating a declining trend.
- In FY2025, shareholders' equity increased 24.4% year-over-year.
- Peak shareholders' equity was recorded in FY2021.
- Lowest shareholders' equity in the period was in FY2024.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.93 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $184.1M | +24.4% |
| FY2024 | $147.9M | -14.8% |
| FY2023 | $173.6M | -46.6% |
| FY2022 | $325.2M | -29.1% |
| FY2021 | $458.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026